专家文章 | 崔一民

搜索
登录

热心肠智库专家文章 | 崔一民

2024

CAIUPHAR ECR review: The cGAS-STING pathway: Novel functions beyond innate immune and emerging therapeutic opportunities

Pharmacol Res, 10.1016/j.phrs.2024.107063

2023

CAUrinary tract infections and genital mycotic infections associated with SGLT‑2 inhibitors: an analysis of the FDA Adverse Event Reporting System

EXPERT OPIN DRUG SAF, 10.1080/14740338.2023.2288897

CAA first-in-human study of Brozopentyl Sodium, following single and multiple ascending intravenous infusion in Chinese healthy volunteers

EUR J PHARM SCI, 10.1016/j.ejps.2023.106663

CAPlatelet factor 4(PF4) and its multiple roles in diseases

BLOOD REV, 10.1016/j.blre.2023.101155

CAPharmacokinetic/LDL-C and exposure-response analysis of tafolecimab in Chinese hypercholesterolemia patients: Results from phase I, II, and III studies

CTS, 10.1111/cts.13674

CAIdentification of immune-associated signatures and potential therapeutic targets for pulmonary arterial hypertension

JCMM, 10.1111/jcmm.17962

CAOptimal anti-platelet therapy for older patients with acute coronary syndrome: a network meta-analysis of randomized trials comprising 59,284 older patients

J THROMB THROMBOLYS, 10.1007/s11239-023-02875-x

CAA Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes

ADV THER, 10.1007/s12325-023-02536-8

CAGenetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study

CLIN TRANSL MED, 10.1002/ctm2.1263

CASafety, Tolerability, and Pharmacokinetics of Recombinant Human Neuregulin-1 in Healthy Chinese Subjects

AM J CARDIOVASC DRUG, 10.1007/s40256-023-00585-6

CAA novel immunogenic cell death-related subtype classification and risk signature for predicting prognosis and immunotherapy efficacy in gastric cancer

Front Immunol, 10.3389/fimmu.2023.1162876

CAPopulation pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis

FPHAR, 10.3389/fphar.2023.1132367

FACAHematologic side effects of immune checkpoint inhibitor with or without chemotherapy in patients with advanced and metastatic gastrointestinal cancer: A systematic review and network meta-analysis of phase 3 trials

FPHAR, 10.3389/fphar.2023.1163971

CAIdentification of genetic biomarkers associated with pharmacokinetics and pharmacodynamics of apixaban in Chinese healthy volunteers

EXPERT OPIN DRUG MET, 10.1080/17425255.2023.2184344

CANew perspectives on the induction and acceleration of immune-associated thrombosis by PF4 and VWF

Front Immunol, 10.3389/fimmu.2023.1098665

CADiscovery of C19-9 as a novel non-RGD inhibitor of αvβ3 to overcome enzalutamide resistance in castration-resistant prostate cancer

SIGNAL TRANSDUCT TAR, 10.1038/s41392-022-01236-z

CAThe challenges and opportunities of αvβ3-based therapeutics in cancer: From bench to clinical trials

Pharmacol Res, 10.1016/j.phrs.2023.106694

CAIntegrated Pharmacokinetics/Pharmacodynamics Model and Simulation of the Ticagrelor Effect on Patients with Acute Coronary Syndrome

CLIN PHARMACOKINET, 10.1007/s40262-022-01208-0

CAUrinary Eubacterium sp. CAG:581 Promotes Non-Muscle Invasive Bladder Cancer (NMIBC) Development through the ECM1/MMP9 Pathway

Cancers, 10.3390/cancers15030809

CATargeting integrin pathways: mechanisms and advances in therapy

SIGNAL TRANSDUCT TAR, 10.1038/s41392-022-01259-6